Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37116523

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2023 May 13
First author
Erba HP

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2023 May 13;401(10388):1546-1548. doi: 10.1016/S0140-6736(23)00617-7.
    note
    Source null
    related pmid
    37116522
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2023 Aug;20(8):504. doi: 10.1038/s41571-023-00787-6.
    note
    Source null
    related pmid
    37253972
    relationship
    Comment in
  3. citation
    Lancet. 2023 Oct 14;402(10410):1328. doi: 10.1016/S0140-6736(23)02235-3.
    note
    Source null
    related pmid
    37838437
    relationship
    Erratum in

Authors and identifiers

  1. name
    Erba HP
    type
    Author
  2. name
    Montesinos P
    type
    Author
  3. name
    Kim HJ
    type
    Author
  4. name
    Patkowska E
    type
    Author
  5. name
    Vrhovac R
    type
    Author
  6. name
    Žák P
    type
    Author
  7. name
    Wang PN
    type
    Author
  8. name
    Mitov T
    type
    Author
  9. name
    Hanyok J
    type
    Author
  10. name
    Kamel YM
    type
    Author
  11. name
    Rohrbach JEC
    type
    Author
  12. name
    Liu L
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Erba HP
    type
    Author
  2. name
    Montesinos P
    type
    Author
  3. name
    Kim HJ
    type
    Author
  4. name
    Patkowska E
    type
    Author
  5. name
    Vrhovac R
    type
    Author
  6. name
    Žák P
    type
    Author
  7. name
    Wang PN
    type
    Author
  8. name
    Mitov T
    type
    Author
  9. name
    Hanyok J
    type
    Author
  10. name
    Kamel YM
    type
    Author
  11. name
    Rohrbach JEC
    type
    Author
  12. name
    Liu L
    type
    Author
bibliography ids
  1. nci-bib-5508082f6dbb44dcce5a867d
book metadata
content sha256
6755d0e3dbb62a40cbe5c7260a994e3ec2b9faeed4c0de0a7ef91df53bf270eb
document type
citation
dois
  1. 10.1016/S0140-6736(23)00464-6
electronic publication date
display
2023 Apr 25
precision
day
year
2023
evidence scope
bibliographic_metadata_only
id
pubmed:37116523
immutable id
pubmed:37116523@6755d0e3dbb62a40cbe5c7260a994e3ec2b9faeed4c0de0a7ef91df53bf270eb
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10388
name
Lancet (London, England)
nlm unique id
2985213R
pages
1571-1583
volume
401
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2023 May 13;401(10388):1546-1548. doi: 10.1016/S0140-6736(23)00617-7.
    note
    Source null
    related pmid
    37116522
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2023 Aug;20(8):504. doi: 10.1038/s41571-023-00787-6.
    note
    Source null
    related pmid
    37253972
    relationship
    Comment in
  3. citation
    Lancet. 2023 Oct 14;402(10410):1328. doi: 10.1016/S0140-6736(23)02235-3.
    note
    Source null
    related pmid
    37838437
    relationship
    Erratum in
outcomes validated
false
pmid
37116523
provenance
batch id
5329a5d0877ee70ecd11
provider
NCBI PubMed ESummary
record sha256
0efd0c469db2cc362ebaf0168c416625e128fa64610a46bf83f74a00edd62225
response sha256
bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
retrieved at
2026-09-09T23:48:15.763286+00:00
publication date
display
2023 May 13
precision
day
year
2023
publication types
  1. Randomized Controlled Trial
  2. Clinical Trial, Phase III
  3. Journal Article
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/37116523/
title
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.

Preserved source evidence · Not medical advice